SCHEMBL25745792

SCHEMBL25745792

Cc1cc(C(F)(F)F)n(CC2CCOCC2)n1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CRHR1 P34998 4/20 0.39
▸ SLC2A1 P11166 1/20 0.39
▸ SLC2A2 P11168 1/20 0.39
▸ SLC2A3 P11169 1/20 0.39
▸ CNR2 P34972 4/20 0.35
▸ CNR1 P21554 2/20 0.35
▸ EBP Q15125 1/20 0.35
▸ GRM2 Q14416 2/20 0.35
▸ MAP3K14 Q99558 1/20 0.35
▸ SLC6A2 P23975 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34
▸ SLC6A3 Q01959 1/20 0.34
▸ SLC34A1 Q06495 1/20 0.34
▸ BRD4 O60885 2/20 0.34
▸ BAZ2A Q9UIF9 1/20 0.34
▸ SLC16A3 O15427 1/20 0.34
▸ SLC16A1 P53985 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25747166 0.84 CRHR1 (0.38) CRHR1SLC2A1SLC2A2SLC2A3CNR2
SCHEMBL25745791 0.84 CRHR1 (0.42) CRHR1CNR2CNR1GRM2SLC6A2
SCHEMBL24815457 0.83 CNR2 (0.39) SLC2A1SLC2A2SLC2A3CNR2CNR1
SCHEMBL1989809 0.83 CRHR1 (0.41) CRHR1CNR2CNR1GRM2SLC6A2
SCHEMBL24007545 0.83 CRHR1 (0.43) CRHR1CNR2CNR1GRM2SLC34A1
SCHEMBL1848906 0.83 CRHR1 (0.41) CRHR1CNR2CNR1GRM2SLC6A2
SCHEMBL24007868 0.83 PDE8B (0.37) SLC2A1SLC2A2SLC2A3CNR2CNR1
SCHEMBL27326744 0.83 SLC6A2 (0.41) CRHR1CNR2CNR1GRM2SLC6A2
SCHEMBL24816265 0.79 CNR2 (0.40) CNR2CNR1MAP3K14
SCHEMBL21960869 0.78 L3MBTL1 (0.42) CRHR1SLC2A1SLC2A2SLC2A3CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors JAK2, JAK3, STAT5B CRHR1 3851/4885SLC2A1 4352/4885SLC2A2 4191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback